WORCESTER, Mass., March 23, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) has demanded a retraction of and apologies for the inaccuracies in an online article published to TheStreet.com on March 19. In an entry titled "Biotech Stock Mailbag: Generex," TheStreet.com columnist Adam Feuerstein makes erroneous claims about Generex and its flagship product Generex Oral-lyn™, an oral insulin spray currently in Phase III clinical trials for the treatment of Type I and Type II diabetes. Generex also wishes to correct the public record by making clear the facts as outlined in the letter to TheStreet.com's counsel:
